Nebenwirkungen · Mektovi
Mektovi 15 mg film-coated tablets Mektovi 45 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 13
HOS-140027 · Präparat HOS-098436
Haemorrhage Haemorrhagic events were observed in 16.7% (62/372) of patients in the Combo 450 ISP. Most events were Grade 1 or 2:13.2% (49/372) and 3.5% (13/372) were Grade≥ 3. Few patients requiring dose interruptions or dose reductions (2.4% or 9/372). Haemorrhagic events led to discontinuation of treatment in 0.8 % (3/372) of patients. The most frequent haemorrhagic events were haematuria in 2.7 % (10/372) of patients, haematochezia in 2.7% (10/372) and rectal haemorrhage in 2.2% (8/372) of patients. Fatal gastric ulcer haemorrhage with multiple organ failure as a concurrent cause of death,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-05T17:08:00Z · SHA-256 08ad2922c2ddc9f92addbbd839b466e9afc2c43b31a5f2435e8602f8f26327da · Passage 6c92e99c9b7e8553c9fb4247fcd28229f32eb6906ccb895109311f3780cb123f · Zeichen 10625–11224 im Abschnitt